NO316024B1 - Fusjonsprotein og antistoff som spesifikt binder til CD40CR - Google Patents
Fusjonsprotein og antistoff som spesifikt binder til CD40CR Download PDFInfo
- Publication number
- NO316024B1 NO316024B1 NO19930521A NO930521A NO316024B1 NO 316024 B1 NO316024 B1 NO 316024B1 NO 19930521 A NO19930521 A NO 19930521A NO 930521 A NO930521 A NO 930521A NO 316024 B1 NO316024 B1 NO 316024B1
- Authority
- NO
- Norway
- Prior art keywords
- cell
- antibody
- molecule
- protein
- cd40cr
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 33
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 33
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 96
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 66
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 230000000284 resting effect Effects 0.000 claims abstract description 40
- 239000000427 antigen Substances 0.000 claims abstract description 25
- 102000036639 antigens Human genes 0.000 claims abstract description 25
- 108091007433 antigens Proteins 0.000 claims abstract description 25
- 230000004913 activation Effects 0.000 claims abstract description 17
- 210000002443 helper t lymphocyte Anatomy 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 239000012634 fragment Substances 0.000 claims description 29
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 230000004069 differentiation Effects 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 230000000340 anti-metabolite Effects 0.000 claims description 5
- 229940100197 antimetabolite Drugs 0.000 claims description 5
- 239000002256 antimetabolite Substances 0.000 claims description 5
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- 108700031361 Brachyury Proteins 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003844 B-cell-activation Effects 0.000 abstract description 25
- 230000004927 fusion Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 5
- 208000026935 allergic disease Diseases 0.000 abstract description 5
- 230000007815 allergy Effects 0.000 abstract description 5
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 4
- 230000000903 blocking effect Effects 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 3
- 208000003455 anaphylaxis Diseases 0.000 abstract description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract description 2
- 206010038997 Retroviral infections Diseases 0.000 abstract description 2
- 230000001363 autoimmune Effects 0.000 abstract description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 abstract description 2
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 abstract description 2
- 230000016784 immunoglobulin production Effects 0.000 abstract description 2
- 230000006698 induction Effects 0.000 abstract description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 50
- 239000003446 ligand Substances 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 102100035920 Probable hydrolase PNKD Human genes 0.000 description 40
- 210000000170 cell membrane Anatomy 0.000 description 34
- 238000000034 method Methods 0.000 description 33
- 230000006819 RNA synthesis Effects 0.000 description 20
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 11
- 241000699800 Cricetinae Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 101000850762 Homo sapiens TNF receptor-associated factor 3 Proteins 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 6
- 108010002616 Interleukin-5 Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000009743 cell cycle entry Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229940100602 interleukin-5 Drugs 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 230000002942 anti-growth Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000004727 humoral immunity Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010063916 CD40 Antigens Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000003133 propidium iodide exclusion Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- KTEGIOKCTFJUDO-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;butanediamide Chemical compound NC(=O)CCC(N)=O.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 KTEGIOKCTFJUDO-UFLZEWODSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000037914 B-cell disorder Diseases 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100232925 Mus musculus Il4 gene Proteins 0.000 description 1
- 101100125879 Mus musculus Il5 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000007837 negative regulation of B cell activation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- -1 platinum coordination complex Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000005368 positive regulation of B cell activation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83579992A | 1992-02-14 | 1992-02-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO930521D0 NO930521D0 (no) | 1993-02-12 |
| NO930521L NO930521L (no) | 1993-08-16 |
| NO316024B1 true NO316024B1 (no) | 2003-12-01 |
Family
ID=25270498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19930521A NO316024B1 (no) | 1992-02-14 | 1993-02-12 | Fusjonsprotein og antistoff som spesifikt binder til CD40CR |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6376459B1 (ja) |
| EP (2) | EP0555880B1 (ja) |
| JP (2) | JP4148537B2 (ja) |
| KR (1) | KR100301146B1 (ja) |
| AT (1) | ATE273998T1 (ja) |
| AU (2) | AU3298893A (ja) |
| CA (1) | CA2089229C (ja) |
| DE (1) | DE69333591T2 (ja) |
| DK (1) | DK0555880T3 (ja) |
| ES (1) | ES2225820T3 (ja) |
| FI (1) | FI117508B (ja) |
| IL (1) | IL104684A0 (ja) |
| NO (1) | NO316024B1 (ja) |
| NZ (1) | NZ245898A (ja) |
| PT (1) | PT555880E (ja) |
| ZA (1) | ZA931013B (ja) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5962406A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5961974A (en) * | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
| DK0822199T3 (da) * | 1991-10-25 | 2004-12-27 | Amgen Inc | N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US7070777B1 (en) * | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| AU5098493A (en) * | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| US5869049A (en) * | 1993-09-02 | 1999-02-09 | Trustees Of Dartmouth College | Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists |
| KR100398819B1 (ko) | 1993-09-02 | 2004-02-05 | 트러스티스 오브 다트마우스 칼리지 | gp39길항제를포함하는약제조성물 |
| CN1137726C (zh) * | 1993-09-02 | 2004-02-11 | 达特茅斯学院理事 | 延长体液免疫抑制的方法 |
| ATE188487T1 (de) * | 1993-09-02 | 2000-01-15 | Dartmouth College | Anti-gp39 antikoerper und deren verwendungen |
| AU1059095A (en) * | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| US5683693A (en) * | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
| MX9605088A (es) | 1994-04-28 | 1997-08-30 | Boehringer Ingelheim Pharma | Metodos para proliferar y diferenciar celulas b y sus usos. |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6372208B1 (en) | 1999-09-28 | 2002-04-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
| US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
| US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| WO1996028568A1 (en) | 1995-03-13 | 1996-09-19 | The Regents Of The University Of Michigan | Cd40 binding compositions and methods of using same |
| US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
| US7427492B1 (en) | 1995-06-05 | 2008-09-23 | Human Genome Sciences, Inc. | Polynucleotides encoding human tumor necrosis factor receptor-like2 |
| US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
| CA2224812A1 (en) * | 1995-06-22 | 1997-01-09 | Biogen, Inc. | Crystals of fragments of cd40 ligand and their use |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| IL125928A (en) * | 1996-03-20 | 2002-11-10 | Bristol Myers Squibb Co | The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations |
| EA004401B1 (ru) * | 1996-07-08 | 2004-04-29 | Дзе Трастиз Оф Колумбия Юниверсити Ин Дзе Сити Оф Нью Йорк | Терапевтическое применение т-вам(cd40l)-технологии для лечения заболеваний с участием клеток гладкой мускулатуры |
| JP2002507967A (ja) * | 1997-06-20 | 2002-03-12 | パンゲネチックス・ベー・ファウ | 疾病治療のための抗ｃｄ４０ｌイムノトキシン |
| CA2223225A1 (en) * | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| CN1173735C (zh) * | 1998-04-03 | 2004-11-03 | 达特茅斯学院理事 | 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用 |
| IL130989A0 (en) * | 1999-07-20 | 2001-01-28 | Compugen Ltd | Variants of alternative splicing |
| AU2001251612A1 (en) | 2000-04-14 | 2001-10-30 | Millennium Pharmaceuticals, Inc. | Roles of jak/stat family members in tolerance induction |
| AU2001296507A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Human anti-cd40 antibodies |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| AU2003206045A1 (en) * | 2002-02-22 | 2003-09-09 | Compugen Ltd. | CD40 splice variants, method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US20030219436A1 (en) * | 2002-03-15 | 2003-11-27 | Ledbetter Jeffrey A. | Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein |
| JP2005535572A (ja) | 2002-04-12 | 2005-11-24 | メディミューン，インコーポレーテッド | 組換え抗インターロイキン−９抗体 |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| EP1670492A4 (en) | 2003-09-29 | 2009-07-08 | Warren Pharmaceuticals Inc | FABRIC PROTECTION CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPTICEMIA AND THE FORMATION OF ADHESIONS |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
| KR20070047327A (ko) | 2004-07-26 | 2007-05-04 | 비오겐 아이덱 엠에이 아이엔씨. | 항-ｃｄ154 항체 |
| US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| US20060148080A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Methods for supporting and producing human cells and tissues in non-human mammal hosts |
| SI1912675T1 (sl) * | 2005-07-25 | 2014-07-31 | Emergent Product Development Seattle, Llc | zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20 |
| CA2654317A1 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
| US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
| US8697846B2 (en) * | 2007-08-15 | 2014-04-15 | Emory University | Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology |
| PT2132228E (pt) | 2008-04-11 | 2011-10-11 | Emergent Product Dev Seattle | Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional |
| KR101721707B1 (ko) | 2008-11-28 | 2017-03-30 | 에모리 유니버시티 | 감염 및 종양 치료 방법 |
| MX354243B (es) | 2011-04-21 | 2018-02-20 | Bristol Myers Squibb Co | Polipeptidos anticuerpos que antagonizan cd40. |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
| EP3592839B1 (en) * | 2017-03-07 | 2023-07-05 | Universität Basel | Mr1 restricted t cell receptors for cancer immunotherapy |
| JP2020521745A (ja) | 2017-05-24 | 2020-07-27 | エイエルエス・セラピー・デベロップメント・インスティテュートＡＬＳ Ｔｈｅｒａｐｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｉｎｓｔｉｔｕｔｅ | 治療用抗ｃｄ４０リガンド抗体 |
| TW201900213A (zh) * | 2017-05-27 | 2019-01-01 | 美商免疫醫療公司 | 免疫球蛋白ａ陽性細胞的調節 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| DE3815472A1 (de) * | 1988-05-06 | 1989-11-16 | Centre Regional De Transfusion | Monoklonaler antikoerper und seine verwendung |
| DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| TR199902191T2 (xx) | 1997-01-10 | 1999-12-21 | Biogen, Inc. | Anti-CD40L bile�ikleri ile lupus nefritis tedavisi |
| AU5623398A (en) | 1997-03-07 | 1998-09-22 | Biogen, Inc. | Methods of therapeutic administration of anti-cd40l compounds |
| WO1999000143A1 (en) | 1997-06-27 | 1999-01-07 | Biogen, Inc. | Cd154 blockade therapy for autoimmune diseases |
-
1993
- 1993-02-10 CA CA2089229A patent/CA2089229C/en not_active Expired - Fee Related
- 1993-02-10 IL IL104684A patent/IL104684A0/xx not_active IP Right Cessation
- 1993-02-11 FI FI930605A patent/FI117508B/fi not_active IP Right Cessation
- 1993-02-12 ES ES93102279T patent/ES2225820T3/es not_active Expired - Lifetime
- 1993-02-12 EP EP93102279A patent/EP0555880B1/en not_active Revoked
- 1993-02-12 NO NO19930521A patent/NO316024B1/no not_active IP Right Cessation
- 1993-02-12 NZ NZ245898A patent/NZ245898A/en not_active IP Right Cessation
- 1993-02-12 DE DE69333591T patent/DE69333591T2/de not_active Expired - Lifetime
- 1993-02-12 DK DK93102279T patent/DK0555880T3/da active
- 1993-02-12 AT AT93102279T patent/ATE273998T1/de active
- 1993-02-12 PT PT93102279T patent/PT555880E/pt unknown
- 1993-02-12 EP EP04012091A patent/EP1489099A3/en not_active Withdrawn
- 1993-02-12 ZA ZA931013A patent/ZA931013B/xx unknown
- 1993-02-12 AU AU32988/93A patent/AU3298893A/en not_active Abandoned
- 1993-02-13 KR KR1019930002045A patent/KR100301146B1/ko not_active IP Right Cessation
- 1993-02-15 JP JP02553093A patent/JP4148537B2/ja not_active Expired - Lifetime
- 1993-08-31 US US08/114,944 patent/US6376459B1/en not_active Expired - Lifetime
-
1996
- 1996-11-26 AU AU71980/96A patent/AU701306B2/en not_active Expired
-
2003
- 2003-10-16 JP JP2003356578A patent/JP3984944B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-10 US US11/127,046 patent/US7445781B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2225820T3 (es) | 2005-03-16 |
| PT555880E (pt) | 2004-12-31 |
| AU701306B2 (en) | 1999-01-28 |
| EP0555880A2 (en) | 1993-08-18 |
| EP1489099A2 (en) | 2004-12-22 |
| US6376459B1 (en) | 2002-04-23 |
| KR100301146B1 (ko) | 2001-10-22 |
| US7445781B2 (en) | 2008-11-04 |
| JP4148537B2 (ja) | 2008-09-10 |
| ZA931013B (en) | 1993-09-20 |
| AU7198096A (en) | 1997-02-06 |
| JP3984944B2 (ja) | 2007-10-03 |
| ATE273998T1 (de) | 2004-09-15 |
| JP2004115527A (ja) | 2004-04-15 |
| DK0555880T3 (da) | 2004-12-06 |
| DE69333591T2 (de) | 2005-09-01 |
| MX9300768A (es) | 1997-09-30 |
| EP1489099A3 (en) | 2008-02-20 |
| US20060008460A1 (en) | 2006-01-12 |
| CA2089229C (en) | 2010-04-13 |
| NO930521D0 (no) | 1993-02-12 |
| NO930521L (no) | 1993-08-16 |
| FI117508B (fi) | 2006-11-15 |
| FI930605A0 (fi) | 1993-02-11 |
| AU3298893A (en) | 1993-08-19 |
| IL104684A0 (en) | 1993-06-10 |
| EP0555880A3 (en) | 1994-05-11 |
| NZ245898A (en) | 1995-04-27 |
| JPH06220096A (ja) | 1994-08-09 |
| DE69333591D1 (de) | 2004-09-23 |
| FI930605A (fi) | 1993-08-15 |
| EP0555880B1 (en) | 2004-08-18 |
| KR930017919A (ko) | 1993-09-20 |
| CA2089229A1 (en) | 1993-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316024B1 (no) | Fusjonsprotein og antistoff som spesifikt binder til CD40CR | |
| Noelle et al. | A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. | |
| JP3447733B2 (ja) | Ｔリンパ球表面のヒト糖蛋白質を認識するネズミモノクローナル抗体（５ｃ８） | |
| ES2227513T5 (es) | Citoquina novedosa. | |
| JP3072330B2 (ja) | 自己免疫疾患および悪性疾患の治療のためのｔ細胞リセプターペプチド | |
| AU724856B2 (en) | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody | |
| Bikah et al. | A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5. | |
| JPH07126300A (ja) | ヒトのｂ細胞受容体複合体の特異抗原を認識するモノクローナル抗体 | |
| NO320354B1 (no) | Anvendelse av et CD40-bindende protein som har evne til a binde CD40 og hindrer binding av CD40 til CD40-L ved fremstilling av et middel for forebyggelse eller behandling av en neoplasmatisk sykdom. | |
| WO1994017184A1 (en) | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto | |
| AU8228891A (en) | Surface complexed lymphotoxin | |
| US7476385B2 (en) | Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1 | |
| US6472510B1 (en) | CD40 receptor ligands | |
| Levy et al. | Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA. | |
| JPH07242566A (ja) | 免疫抑制剤 | |
| CA2134655A1 (en) | Modulation of thrombospondin-cd36 interactions | |
| AU743824B2 (en) | Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease | |
| US20020058037A1 (en) | Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease | |
| JPH11509723A (ja) | 抗原特異的グリコシル化阻害因子の製法 | |
| JP2788979B2 (ja) | 新規抗体及びその用途 | |
| Arendt | Physical and functional interactions of the hematopoietic cell-specific protein-tyrosine phosphatase CD45 | |
| KR20000024757A (ko) | 면역억제능이 있는 항-씨디40 리간드 모노클로날 항체 | |
| HU220192B (hu) | Gyógyszerkészítmények a humorális immunitás gátlására | |
| JPH09316100A (ja) | Ｆｃレセプターに対するモノクローナル抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |